Sonnet BioTherapeutics Holdings, Inc. (SONN)

SONN Revenue

Sonnet BioTherapeutics Holdings had revenue of $129.18K in the twelve months ending December 31, 2023, down -49.81% year-over-year. Revenue in the quarter ending December 31, 2023 was $18.63K, a -50.00% decrease year-over-year. In the fiscal year ending September 30, 2023, Sonnet BioTherapeutics Holdings had annual revenue of $147.81K, a decrease of -57.76%.

• Revenue (ttm): $129.18K
• Revenue Growth: -49.81%
• P/S Ratio: 45.62
• Revenue / Employee: $10,765
• Employees: 12
• Market Cap: 5.89M USD

Revenue History

Fiscal Year End	Revenue	Change	Growth
Sep 30, 2023	147.81K	-202.14K	-57.76%
Sep 30, 2022	349.94K	-133.68K	-27.64%
Sep 30, 2021	483.63K	-	-
Sep 30, 2020	0	-	-
Sep 30, 2019	0	-	-
Dec 31, 2018	30.73M	-10.70M	-25.82%
Dec 31, 2017	41.43M	-269.14K	-0.65%
Dec 31, 2016	41.70M	6.35M	17.96%
Dec 31, 2015	35.35M	5.51M	18.46%
Dec 31, 2014	29.84M	21.60M	261.85%
Dec 31, 2013	8.25M	1.40M	20.36%
Dec 31, 2012	6.85M	5.38M	364.05%
Dec 31, 2011	1.48M	1.34M	983.37%
Dec 31, 2010	136.30K	-466.68K	-77.40%
Dec 31, 2009	602.98K	368.92K	157.62%
Dec 31, 2008	234.06K	-297.19K	-55.94%
Dec 31, 2007	531.25K	404.00K	317.51%
Dec 31, 2006	127.24K	122.45K	2,552.00%
Dec 31, 2005	4.80K	-	-
Dec 31, 2004	0	-	-

Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.